It seems clear that the lower the LDL is, the better.

It's been said after all the studies with statins and monoclonal antibodies to PCSK9 that

we have not found or determined what the lower limit of LDL is.

So far the lower the LDL is, the greater the benefit is by decreasing CV complications and death.

This study with PCSK9 Inhibitors shows the benefit all the way down to LDL 19 mg.

Currently most labs show normal range for LDL less than 100-130 mg for adults, which in my opinion

is too high.